Reference
What is Retatrutide?
Retatrutide is a triple agonist — one peptide chain acting at three receptors: GIP, GLP-1 and glucagon. That is a step beyond tirzepatide, which addresses two, and beyond semaglutide, which addresses one.
Classification
| Type | Peptide |
| Family | Triple GIP, GLP-1 and glucagon receptor agonist |
| Origin | Developed by Eli Lilly; investigational, not an approved medicine in any country |
| Supplied as | Lyophilised powder in a sealed vial |
Each receptor added multiplies the design constraints, since the same sequence must satisfy every binding site simultaneously. It is an investigational compound and has not been approved as a medicine anywhere, which distinguishes it from the other two despite their being discussed together.
What this page does not cover
Nothing here describes what Retatrutide does, what it is used for, or whether it is safe. We publish analytical results and ship parcels; we give no guidance on dosing, preparation or use, and that applies to our reference pages as much as to the product pages. The person to ask about any of that is a registered prescriber.
Related by family
Where it came from
Retatrutide is the newest compound in this catalogue by a wide margin. It was first described in 2022 and has never been approved as a medicine anywhere.
First described 2022 — Indianapolis, United States. When was retatrutide created?
Further reading
Retatrutide vs tirzepatide vs semaglutide — one, two or three receptors, and how the three molecules differ in length, origin and status.
More on Retatrutide
- Retatrutide — prices and sizes
- Buying Retatrutide in New Zealand
- When was Retatrutide discovered?
- The Retatrutide certificate of analysis
See Retatrutide in the range · What is a peptide? · Discovery timeline · All reference
